Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

- New data from Phase 3 COV-BARRIER sub-study indicates one death prevented for every six baricitinib-treated patients on mechanical ventilation or ECMO compared to placebo - Data showed 46% risk reduction in mortality by Day 28 and 44% risk reduction in mortality by Day 60 INDIANAPOLIS , Aug.